NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 89 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 2.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | -100.0% | 265 | 0.0% | 0.00% | – |
| Q2 2023 | $1 | 0.0% | 265 | 0.0% | 0.00% | – |
| Q1 2023 | $1 | 0.0% | 265 | 0.0% | 0.00% | – |
| Q4 2022 | $1 | -100.0% | 265 | 0.0% | 0.00% | – |
| Q3 2022 | $3,000 | 0.0% | 265 | 0.0% | 0.00% | – |
| Q2 2022 | $3,000 | -25.0% | 265 | 0.0% | 0.00% | – |
| Q1 2022 | $4,000 | -20.0% | 265 | 0.0% | 0.00% | – |
| Q4 2021 | $5,000 | -16.7% | 265 | 0.0% | 0.00% | – |
| Q3 2021 | $6,000 | +100.0% | 265 | +81.5% | 0.00% | – |
| Q2 2021 | $3,000 | -25.0% | 146 | 0.0% | 0.00% | – |
| Q1 2021 | $4,000 | 0.0% | 146 | +12.3% | 0.00% | – |
| Q4 2020 | $4,000 | -33.3% | 130 | -65.4% | 0.00% | – |
| Q3 2020 | $6,000 | +20.0% | 376 | 0.0% | 0.00% | – |
| Q2 2020 | $5,000 | 0.0% | 376 | 0.0% | 0.00% | – |
| Q1 2020 | $5,000 | -28.6% | 376 | 0.0% | 0.00% | – |
| Q4 2019 | $7,000 | – | 376 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
| Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
| Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
| Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
| Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
| Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
| Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
| Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
| Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |